Safety
Safety comes first, and only a patient and their clinical care team can decide what is safe. This is general information, not medical or legal advice.
Compounded tirzepatide and FDA approval
A:No, compounded tirzepatide is not FDA approved. Compounded tirzepatide is a custom-prepared form of tirzepatide that a licensed compounding pharmacy makes under a prescription.1 The FDA wrote to state nursing boards in 2024 that compounded tirzepatide products do not undergo premarket review for safety, effectiveness, or quality, and thus cannot be FDA approved.2
The FDA-approved tirzepatide medicines are Mounjaro and Zepbound. The South Carolina Attorney General warned in 2026 that compounded tirzepatide sold by med spas, wellness centers, and online retailers is not FDA approved.3 In a 2025 warning letter, the FDA told eDrugstore that its claim of "FDA-Approved Active" was false or misleading, because it implied the compounded product was the same as an FDA-approved product.4
For more about what regulators have found, see our compounded injectable risks. The FDA says compounded drug products can serve an important medical need for certain patients. Its 2024 letter also reports adverse events, some serious, after compounded doses exceeded the dosing or titration schedule of FDA-approved tirzepatide.2
Notice
This article is for informational purposes only. It describes published sources and gives our opinion on what they mean for running a practice. It is not medical or legal advice, it does not create a doctor‑patient or attorney‑client relationship, and it should not be used to make any medical or legal decision. Discuss treatment with a qualified healthcare provider and legal questions with a licensed attorney. What it says about any company, product, or pharmacy comes from the sources cited below, and anything beyond them is our opinion. To report an error, email lazar@fractionalaesthetics.com and we will review it.
How patients see your practice
The FAx audit scores what a prospective patient sees: search, reviews, presence, and AI. It takes two minutes to request and needs no call, and the audit arrives by email within a couple of business days, yours to keep.
More market research
Sofwave usage fees rose 60% in one quarter. What does Sofwave tell investors about practice margins?Sofwave's usage fees rose 60% to $13.3 million in Q3 2026.5 min read About half of body contouring patients were ready at a PA or NP visit. When do the rest return?A PA or nurse practitioner found about half of body contouring patients ready.7 min read Juvéderm sales fell 11.8% year over year. How often do toxin patients add filler?In 2025, 13% of US toxin treatments came with a filler treatment, down from about 21% in 2017.5 min readReferences (4)
- Testing.com, Compounded Tirzepatide: How It Works, Safety, and Cost, 2026. Vendor-published. https://www.testing.com/treatments/compounded-tirzepatide/ Back to where you were ↑
- U.S. Food and Drug Administration, Letter to the National Council of State Boards of Nursing on compounded semaglutide and tirzepatide, 2024. Regulator. https://www.pa.gov/content/dam/copapwp-pagov/en/dos/department-and-offices/bpoa/nursing/fda-safety-alert.pdf Back to where you were ↑
- South Carolina Attorney General, CONSUMER ALERT: Attorney General Alan Wilson warns consumers to be cautious when purchasing unapproved and compounded weight loss medications, 2026. Government. https://www.scag.gov/about-the-office/news/consumer-alert-attorney-general-alan-wilson-warns-consumers-to-be-cautious-when-purchasing-unapproved-and-compounded-weight-loss-medications/ Back to where you were ↑
- U.S. Food and Drug Administration, Warning Letter: eDrugstore MARCS-CMS 716505, 2025. Regulator. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025 Back to where you were ↑